Name: Image-guided In Vivo Tracking of Transplanted Distal Lung Epithelial Progenitor Cells for Pulmonary Fibrosis Using Magnetic Particle Imaging (Video) | JoVE Journal
Uploaded: 2025-06-27T14:40:00.000+00:00
Duration: 7 min 14 s
Description: Learn magnetic particle imaging to track transplanted distal lung epithelial progenitor cells in vivo for pulmonary fibrosis research. This noninvasive method enables real-time monitoring of cell distribution and retention.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

The funding for this study was provided in part by the grant from R01HL153165-01A1 to X.P.L. and R21AI159928-01 to P.W.

All procedures involving animal subjects have been approved by the Michigan State University Institutional Animal Care and Use Committee (IACUC) and involving human subjects have been approved by Corewell Health IRB no. 2017-198. All patients provided written informed consent prior to participation in the study.
Human lung explant samples from Idiopathic Pulmonary Fibrosis (IPF) patients undergoing lung transplantation were collected from Corewell Health. Prior to the transplantation procedure, all patients met the diagnostic criteria for idiopathic pulmonary fibrosis (IPF), characterized by hypoxemia, dyspnea, and reduced lung volume43. Pathological analysis of tissue taken from the distal end of the lung lobe confirmed the presence of fibrosis.
Male NOD/SCID mice were purchased at 8 weeks of age and allowed to acclimate for 1 week and then aged until 12 weeks prior to the procedure.
1. Isolation and expansion of human airway epithelial cells
<ol>
	<li>Place the explanted lung sample on ice to preserve cell integrity during dissection. Identify the bronchus/large airways present in the sample; the small airways are located at the distal portions of the lung sample, furthest away from the large airways. Using sterilized instruments, excise the distal portion of the lung sample and process into smaller portions to aid in the digestion of the tissue. Rinse the sample in Dulbecco&#39;s phosphate-buffered saline (DPBS) to remove excess blood and fluid, then digest the explanted lung tissue containing the small airways in a buffer consisting of protease from Streptomyces griseus, 1x penicillin/streptomycin, DNase I, and 1x Gentamicin in a 50 mL tube. Place the tissue in a 37 &#176;C water bath to rock for approximately 4 h, or until the tissue is sufficiently digested.</li>
	<li>Pass the contents of the 50 mL tube through a sterile 100 &#181;m cell strainer. Rinse the tissue 3x with DPBS&#160;and pass the washes through the strainer. Pellet the cells by centrifugation at 400 &#215; g for 5 min, remove the supernatant, and resuspend the cells in 1 mL of culture medium by pipetting the cell suspension 50x with a pipet set to 500 &#181;L.</li>
	<li>Add the cell suspension to a 75 cm2 culture flask containing the airway epithelial growth medium. Culture the cells at 37 &#176;C, 5% CO2 for approximately 2 weeks.</li>
</ol>
2. Labeling airway epithelial cells with nanoparticles (iron oxide tracer)
<ol>
	<li>When epithelial cultures are 80% confluent, label the cells with iron oxide tracer at a final concentration of 250 &#181;g/mL. Add the appropriate volume of iron oxide tracer to 10 mL of culture medium per flask of epithelial cells and incubate for 48 h. 
	NOTE: Different concentrations of iron oxide tracer (50, 100, 200, and 250 &#181;g/mL) were evaluated for cell labeling followed by their 2D MPI scans (Figure 1A). The concentration of 250 &#181;g/mL, along with 50,000 cells for transplantation, was finalized for this study.</li>
	<li>After 48 h, wash the cells 3x with DPBS&#160;to remove excess nanoparticles.</li>
	<li>Detach the cells using cell-detaching reagent and incubate the cells at 37 &#176;C for 15 min, or until the cells begin to lift from the surface of the flask.</li>
	<li>Collect the cells into a 50 mL tube containing 1 mL of Fetal Bovine Serum. Rinse the flask 3x with 5 mL of DPBS, and add the washes to the 50 mL tube containing the cells.</li>
	<li>Pellet the cells by centrifugation at 400 &#215; g for 5 min. Remove the supernatant and resuspend the cells in 1 mL of culture medium by pipetting the cell suspension 50x with a pipet set to 500 &#181;L.</li>
	<li>Use a hemocytometer to determine the cell concentration and determine the volume of cell suspension required for the in vivo transplantation.</li>
	<li>Aliquot 100 &#181;L of the cell suspension and fix in 4% paraformaldehyde.</li>
</ol>
3. In vitro immunostaining and microscopy
<ol>
	<li>Load the 100 &#181;L aliquot of cell suspension into a cytospin cartridge containing a slide and filter and spin for 5 min at 1,000 rpm.</li>
	<li>Outline the cells on the slide using a hydrophobic pen.</li>
	<li>Wash the slides for 2 x 15 min with DPBS.</li>
	<li>Permeabilize the cells on the slide by incubating with 0.1% Triton X-100 in DPBS for 5 min at room temperature.</li>
	<li>Wash the cells for 2 x 2 min with DPBS.</li>
	<li>Block the slides with 5% bovine serum albumin (BSA)/1% goat serum in DPBS for 2 h.</li>
	<li>Incubate the slides in primary antibody (anti-dextran) in 2.5% BSA/0.5% goat serum in DPBS overnight at 4 &#176;C.</li>
	<li>Remove the primary antibody and wash slides 3 x 5 min in 1x Tris-Buffered Saline with Tween 20 (TBST).</li>
	<li>Incubate the slides with 1:1,000 secondary antibody in 2.5% BSA/0.5% goat serum in DPBS for 1 h at room temperature in the dark.</li>
	<li>Wash slides for 3 x 5 min with 1x TBST.</li>
	<li>Add a nuclear staining agent, 4&#8242;,6-diamidino-2-phenylindole (DAPI), to the slide at a concentration of 1:1,000 in DPBS and allow to incubate at room temperature for 5 min.</li>
	<li>Wash the slides 2 x 5 min with 1x TBST. Remove excess 1x TBST from the slide.</li>
	<li>Add mounting medium with DAPI and place a glass coverslip over slide, being careful to avoid any air bubbles.</li>
	<li>After the slide has set, seal the edges of the coverslip using a clear nail polish.</li>
	<li>Image the slides on a confocal microscope.</li>
</ol>
4. Cell transplantation using intratracheal instillation
<ol>
	<li>Preparation
	<ol>
		<li>Weigh the mouse to calculate the dose of bleomycin (BLM) required for each mouse.</li>
		<li>In a 1.7 mL microcentrifuge tube, prepare the desired BLM&#160;solution (diluted in sterilized saline) in a volume not to exceed 50 &#181;L. 
		NOTE: The drug concentration will vary depending on the experimental goals. BLM at 0.6 U/kg was used for this procedure.</li>
		<li>Load the BLM solution in a pipette. Additionally, preload a syringe with 200 &#181;L of air to ensure that all of the liquid volume is expelled into the trachea. 
		NOTE: After 72 h of BLM treatment, the labeled cell suspension will be administered in a similar fashion.</li>
		<li>Use the cell count obtained from step 2.6 to calculate the volume of cell suspension, containing 50,000 cells, to be administered.</li>
		<li>Anesthetize the mouse by placing it in an induction box connected to the anesthesia unit supplying isoflurane (2.5-3%) until anesthetized. 
		NOTE: The mice are anesthetized twice during the whole procedure: (1) on the day of BLM administration and (2) on the day of intratracheal instillation of cells, which is 72 h after the BLM dose.</li>
		<li>Set up the fiber light intubation kit as shown in Figure 2A with the optical fiber probe passing through the laryngoscope and the catheter. 
		NOTE: The illuminated end of the fiber should be placed just outside (1-2 mm) the catheter tube.</li>
	</ol>
	</li>
	<li>Intratracheal Instillation
	<ol>
		<li>Confirm anesthetization by checking the pedal reflex by pinching the toe in either of the hind legs. Once adequate anesthesia is confirmed, suspend the mouse by its incisors in the supine position on an angled rodent intubation stand (Figure 2B-D).</li>
		<li>Using blunt-ended forceps, carefully grasp the tongue and, in an upward and leftward motion, position the tongue to gain adequate visualization of the larynx.</li>
		<li>Turn on the fiber-optic probe and enter the mouth to approach the trachea. Utilize the magnifier of the laryngoscope for improved visualization of the larynx and locate the vocal cords at the tracheal opening.</li>
		<li>Insert the catheter in the tracheal opening and very carefully detach the laryngoscope and pull it out. Place a tiny droplet of saline (20 &#181;L) at the upper end of the catheter. 
		NOTE: The liquid level will move up and down, aligned with the breathing rate of the mouse. This will confirm the placement of the catheter in the trachea and not mistakenly in the esophagus.</li>
		<li>Attach a syringe with preloaded 200 &#181;L of air and push the droplet inside. Place the cell suspension (&#8804;50 &#181;L) in the catheter and instill it using the air-loaded syringe as previously.</li>
		<li>To prevent the instilled liquid from escaping the trachea, leave the catheter in place for 5-7 s. Then, gently pull out the catheter.</li>
		<li>Maintain the mouse in the same position on the intubation stand for at least 30 s.</li>
		<li>Remove the mouse and put it in a recovery cage placed on a heating pad. Monitor until fully recovered from anesthesia.</li>
	</ol>
	</li>
</ol>
5. Magnetic particle imaging
<ol>
	<li>Anesthetize the mouse by placing it in an induction box connected to the anesthesia unit supplying isoflurane (2-2.5%) until anesthetized.</li>
	<li>Set up the mouse bed in an MPI scanner with the anesthesia line passing under the bed through appropriate connections.</li>
	<li>While the mouse is being sedated, prepare the MPI scanner for imaging. Start the linked software and define a folder name in Project and the scan in Exam name domain for identification, and set the scan parameters according to the requirements. To follow this procedure, use these scan parameters: Scan Type: 2D scan; Scan Mode: Standard; Transmit Channels: Multichannel (Isotropic); Averages per projection: 2.</li>
	<li>Check anesthetization as described in step 4.2.1. Securely place the mouse on the MPI bed as depicted in Figure 2E. 
	NOTE: Make sure that the snout is properly aligned with the in-built nose cone of the bed for proper maintenance of anesthesia during the scanning. 
	CAUTION: Insufficient anesthesia during the scan can cause the mouse to wake up while the scan is running.</li>
	<li>Once the mouse has been placed in the scanner, push the bed inside the bore and click Start Scan.</li>
	<li>After the scan is complete, remove the mouse from the MPI bed and put it in a recovery cage placed on a heating pad. Monitor until fully recovered from anesthesia.</li>
	<li>Analyze the images using image analysis software.</li>
</ol>

<ol><li>Biehl, J. K., Russell, B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Introduction+to+Stem+Cell+Therapy%5BTitle%5D)+AND+%22J+Cardiovasc+Nurs%22%5BJournal%5D)">Introduction to Stem Cell Therapy.</a> J Cardiovasc Nurs. 24 (2), 98-103 (2009).</li>
<li>Herberts, C. A., Kwa, M. S. G., Hermsen, H. P. H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Risk+factors+in+the+development+of+stem+cell+therapy%5BTitle%5D)+AND+%22J+Transl+Med%22%5BJournal%5D)">Risk factors in the development of stem cell therapy.</a> J Transl Med. 9 (1), 29(2011).</li>
<li>Bair, S. M., Brandstadter, J. D., Ayers, E. C., Stadtmauer, E. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Hematopoietic+stem+cell+transplantation+for+blood+cancers+in+the+era+of+precision+medicine+and+immunotherapy%5BTitle%5D)+AND+%22Cancer%22%5BJournal%5D)">Hematopoietic stem cell transplantation for blood cancers in the era of precision medicine and immunotherapy.</a> Cancer. 126 (9), 1837-1855 (2020).</li>
<li>Xuan, L., Liu, Q. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Maintenance+therapy+in+acute+myeloid+leukemia+after+allogeneic+hematopoietic+stem+cell+transplantation%5BTitle%5D)+AND+%22J+Hematol+Oncol%22%5BJournal%5D)">Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.</a> J Hematol Oncol. 14 (1), 4(2021).</li>
<li>Zhu, C., Wu, W., Qu, X. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Mesenchymal+stem+cells+in+osteoarthritis+therapy%3A+a+review%5BTitle%5D)+AND+%22Am+J+Transl+Res%22%5BJournal%5D)">Mesenchymal stem cells in osteoarthritis therapy: a review.</a> Am J Transl Res. 13 (2), 448-461 (2021).</li>
<li>Giorgino, R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Knee+osteoarthritis%3A+Epidemiology%2C+pathogenesis%2C+and+mesenchymal+stem+cells%3A+What+else+is+new%3F+An+update%5BTitle%5D)+AND+%22Int+J+Mol+Sci%22%5BJournal%5D)">Knee osteoarthritis: Epidemiology, pathogenesis, and mesenchymal stem cells: What else is new? An update.</a> Int J Mol Sci. 24 (7), 6405(2023).</li>
<li>Jeyagaran, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Type+1+diabetes+and+engineering+enhanced+islet+transplantation%5BTitle%5D)+AND+%22Adv+Drug+Deliv+Rev%22%5BJournal%5D)">Type 1 diabetes and engineering enhanced islet transplantation.</a> Adv Drug Deliv Rev. 189, 114481(2022).</li>
<li>Shinozaki, M., Nagoshi, N., Nakamura, M., Okano, H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Mechanisms+of+stem+cell+therapy+in+spinal+cord+injuries%5BTitle%5D)+AND+%22Cells%22%5BJournal%5D)">Mechanisms of stem cell therapy in spinal cord injuries.</a> Cells. 10 (10), 2676(2021).</li>
<li>Zipser, C. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Cell-based+and+stem-cell-based+treatments+for+spinal+cord+injury%3A+evidence+from+clinical+trials%5BTitle%5D)+AND+%22Lancet+Neurol%22%5BJournal%5D)">Cell-based and stem-cell-based treatments for spinal cord injury: evidence from clinical trials.</a> Lancet Neurol. 21 (7), 659-670 (2022).</li>
<li>Kim, S. W., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Neural+stem+cells+derived+from+human+midbrain+organoids+as+a+stable+source+for+treating+Parkinson%27s+disease%3A+Midbrain+organoid-NSCs+%28Og-NSC%29+as+a+stable+source+for+PD+treatment%5BTitle%5D)+AND+%22Prog+Neurobiol%22%5BJournal%5D)">Neural stem cells derived from human midbrain organoids as a stable source for treating Parkinson's disease: Midbrain organoid-NSCs (Og-NSC) as a stable source for PD treatment.</a> Prog Neurobiol. 204, 102086(2021).</li>
<li>Nie, L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Directional+induction+of+neural+stem+cells%2C+a+new+therapy+for+neurodegenerative+diseases+and+ischemic+stroke%5BTitle%5D)+AND+%22Cell+Death+Discov%22%5BJournal%5D)">Directional induction of neural stem cells, a new therapy for neurodegenerative diseases and ischemic stroke.</a> Cell Death Discov. 9 (1), 215(2023).</li>
<li>Yue, C., Feng, S., Chen, Y., Jing, N. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+therapeutic+prospects+and+challenges+of+human+neural+stem+cells+for+the+treatment+of+Alzheimer%27s+Disease%5BTitle%5D)+AND+%22Cell+Regen%22%5BJournal%5D)">The therapeutic prospects and challenges of human neural stem cells for the treatment of Alzheimer's Disease.</a> Cell Regen. 11 (1), 28(2022).</li>
<li>Kim, J. -H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Human+pluripotent+stem+cell-derived+alveolar+organoids+for+modeling+pulmonary+fibrosis+and+drug+testing%5BTitle%5D)+AND+%22Cell+Death+Discov%22%5BJournal%5D)">Human pluripotent stem cell-derived alveolar organoids for modeling pulmonary fibrosis and drug testing.</a> Cell Death Discov. 7 (1), 48(2021).</li>
<li>Cheng, W., Zeng, Y., Wang, D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Stem+cell-based+therapy+for+pulmonary+fibrosis%5BTitle%5D)+AND+%22Stem+Cell+Res+Ther%22%5BJournal%5D)">Stem cell-based therapy for pulmonary fibrosis.</a> Stem Cell Res Ther. 13 (1), 492(2022).</li>
<li>Milman Krentsis, I., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Lung+cell+transplantation+for+pulmonary+fibrosis%5BTitle%5D)+AND+%22Sci+Adv%22%5BJournal%5D)">Lung cell transplantation for pulmonary fibrosis.</a> Sci Adv. 10 (34), eadk2524(2024).</li>
<li>Suezawa, T., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Disease+modeling+of+pulmonary+fibrosis+using+human+pluripotent+stem+cell-derived+alveolar+organoids%5BTitle%5D)+AND+%22Stem+Cell+Rep%22%5BJournal%5D)">Disease modeling of pulmonary fibrosis using human pluripotent stem cell-derived alveolar organoids.</a> Stem Cell Rep. 16 (12), 2973-2987 (2021).</li>
<li>Madrid, M., Sumen, C., Aivio, S., Saklayen, N. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Autologous+induced+pluripotent+stem+cell-based+cell+therapies%3A+Promise%2C+progress%2C+and+challenges%5BTitle%5D)+AND+%22Curr+Protoc%22%5BJournal%5D)">Autologous induced pluripotent stem cell-based cell therapies: Promise, progress, and challenges.</a> Curr Protoc. 1 (3), e88(2021).</li>
<li>Balistreri, C. R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Stem+cell+therapy%3A+old+challenges+and+new+solutions%5BTitle%5D)+AND+%22Mol+Biol+Rep%22%5BJournal%5D)">Stem cell therapy: old challenges and new solutions.</a> Mol Biol Rep. 47 (4), 3117-3131 (2020).</li>
<li>Richeldi, L., Collard, H. R., Jones, M. G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Idiopathic+pulmonary+fibrosis%5BTitle%5D)+AND+%22Lancet%22%5BJournal%5D)">Idiopathic pulmonary fibrosis.</a> Lancet. 389 (10082), 1941-1952 (2017).</li>
<li>Tzouvelekis, A., Antoniadis, A., Bouros, D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Stem+cell+therapy+in+pulmonary+fibrosis%5BTitle%5D)+AND+%22Curr+Opin+Pulm+Med%22%5BJournal%5D)">Stem cell therapy in pulmonary fibrosis.</a> Curr Opin Pulm Med. 17 (5), 368-373 (2011).</li>
<li>Rawlins, E. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Lung+epithelial+progenitor+cells%5BTitle%5D)+AND+%22Proc+Am+Thorac+Soc%22%5BJournal%5D)">Lung epithelial progenitor cells.</a> Proc Am Thorac Soc. 5 (6), 675-681 (2008).</li>
<li>Han, M. -M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Nanoengineered+mesenchymal+stem+cell+therapy+for+pulmonary+fibrosis+in+young+and+aged+mice%5BTitle%5D)+AND+%22Sci+Adv%22%5BJournal%5D)">Nanoengineered mesenchymal stem cell therapy for pulmonary fibrosis in young and aged mice.</a> Sci Adv. 9 (29), eadg5358(2023).</li>
<li>Averyanov, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((First-in-human+high-cumulative-dose+stem+cell+therapy+in+idiopathic+pulmonary+fibrosis+with+rapid+lung+function+decline%5BTitle%5D)+AND+%22Stem+Cells+Transl+Med%22%5BJournal%5D)">First-in-human high-cumulative-dose stem cell therapy in idiopathic pulmonary fibrosis with rapid lung function decline.</a> Stem Cells Transl Med. 9 (1), 6-16 (2019).</li>
<li>Glassberg, M. K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Allogeneic+human+mesenchymal+stem+cells+in+patients+with+idiopathic+pulmonary+fibrosis+via+intravenous+delivery+%28AETHER%29%3A+A+phase+I+safety+clinical+trial%5BTitle%5D)+AND+%22Chest%22%5BJournal%5D)">Allogeneic human mesenchymal stem cells in patients with idiopathic pulmonary fibrosis via intravenous delivery (AETHER): A phase I safety clinical trial.</a> Chest. 151 (5), 971-981 (2017).</li>
<li>Zhao, X., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Adipose-derived+mesenchymal+stem+cell+therapy+for+reverse+bleomycin-induced+experimental+pulmonary+fibrosis%5BTitle%5D)+AND+%22Sci+Rep%22%5BJournal%5D)">Adipose-derived mesenchymal stem cell therapy for reverse bleomycin-induced experimental pulmonary fibrosis.</a> Sci Rep. 13 (1), 13183(2023).</li>
<li>Tzouvelekis, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+prospective%2C+non-randomized%2C+no+placebo-controlled%2C+phase+Ib+clinical+trial+to+study+the+safety+of+the+adipose+derived+stromal+cells-stromal+vascular+fraction+in+idiopathic+pulmonary+fibrosis%5BTitle%5D)+AND+%22J+Transl+Med%22%5BJournal%5D)">A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis.</a> J Transl Med. 11 (1), 171(2013).</li>
<li>Tzouvelekis, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Stem+cell+therapy+for+idiopathic+pulmonary+fibrosis%3A+a+protocol+proposal%5BTitle%5D)+AND+%22J+Transl+Med%22%5BJournal%5D)">Stem cell therapy for idiopathic pulmonary fibrosis: a protocol proposal.</a> J Transl Med. 9 (1), 182(2011).</li>
<li>Choi, S. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Classical+monocyte-derived+macrophages+as+therapeutic+targets+of+umbilical+cord+mesenchymal+stem+cells%3A+comparison+of+intratracheal+and+intravenous+administration+in+a+mouse+model+of+pulmonary+fibrosis%5BTitle%5D)+AND+%22Respir+Res%22%5BJournal%5D)">Classical monocyte-derived macrophages as therapeutic targets of umbilical cord mesenchymal stem cells: comparison of intratracheal and intravenous administration in a mouse model of pulmonary fibrosis.</a> Respir Res. 24 (1), 68(2023).</li>
<li>Llontop, P., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Airway+transplantation+of+adipose+stem+cells+protects+against+bleomycin-induced+pulmonary+fibrosis%5BTitle%5D)+AND+%22J+Investig+Med%22%5BJournal%5D)">Airway transplantation of adipose stem cells protects against bleomycin-induced pulmonary fibrosis.</a> J Investig Med. 66 (4), 739-746 (2018).</li>
<li>Gad, E. S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+anti-fibrotic+and+anti-inflammatory+potential+of+bone+marrow-derived+mesenchymal+stem+cells+and+nintedanib+in+bleomycin-induced+lung+fibrosis+in+rats%5BTitle%5D)+AND+%22Inflammation%22%5BJournal%5D)">The anti-fibrotic and anti-inflammatory potential of bone marrow-derived mesenchymal stem cells and nintedanib in bleomycin-induced lung fibrosis in rats.</a> Inflammation. 43 (1), 123-134 (2020).</li>
<li>Aal Porzionato,, et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Intratracheal+administration+of+mesenchymal+stem+cell-derived+extracellular+vesicles+reduces+lung+injuries+in+a+chronic+rat+model+of+bronchopulmonary+dysplasia%5BTitle%5D)+AND+%22Am+Jl+Physiol+Lung+Cell+Mol+Physiol%22%5BJournal%5D)">Intratracheal administration of mesenchymal stem cell-derived extracellular vesicles reduces lung injuries in a chronic rat model of bronchopulmonary dysplasia.</a> Am Jl Physiol Lung Cell Mol Physiol. 320 (5), L688-L704 (2021).</li>
<li>Ortiz-Muñoz, G., Looney, M. R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Non-invasive+Intratracheal+Instillation+in+Mice%5BTitle%5D)+AND+%22Bio+Protoc%22%5BJournal%5D)">Non-invasive Intratracheal Instillation in Mice.</a> Bio Protoc. 5 (12), e1504(2015).</li>
<li>Srinivas, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Imaging+of+cellular+therapies%5BTitle%5D)+AND+%22Adv+Drug+Deliv+Rev%22%5BJournal%5D)">Imaging of cellular therapies.</a> Adv Drug Deliv Rev. 62 (11), 1080-1093 (2010).</li>
<li>Li, Z., Tong, L., Zhao, H., He, Z. <a target="_blank" href="http://scholar.google.com/scholar?hl=en&safe=off&q=author%3aLi%2C+Z+%22Medical+Imaging+in+Clinical+Practice%22">Medical Imaging in Clinical Practice</a>. Erondu, F. O. , IntechOpen. (2013).</li>
<li>Knopp, T., Gdaniec, N., Möddel, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Magnetic+particle+imaging%3A+from+proof+of+principle+to+preclinical+applications%5BTitle%5D)+AND+%22Phys+Med+Biol%22%5BJournal%5D)">Magnetic particle imaging: from proof of principle to preclinical applications.</a> Phys Med Biol. 62 (14), R124-R178 (2017).</li>
<li>Borgert, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Fundamentals+and+applications+of+magnetic+particle+imaging%5BTitle%5D)+AND+%22J+Cardiovasc+Computed+Tomogr%22%5BJournal%5D)">Fundamentals and applications of magnetic particle imaging.</a> J Cardiovasc Computed Tomogr. 6 (3), 149-153 (2012).</li>
<li>Mohapatra, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Principles+and+applications+of+magnetic+nanomaterials+in+magnetically+guided+bioimaging%5BTitle%5D)+AND+%22Mater+Today+Phys%22%5BJournal%5D)">Principles and applications of magnetic nanomaterials in magnetically guided bioimaging.</a> Mater Today Phys. 32, 101003(2023).</li>
<li>Pablico-Lansigan, M. H., Situ, S. F., Samia, A. C. S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Magnetic+particle+imaging%3A+advancements+and+perspectives+for+real-time+in+vivo+monitoring+and+image-guided+therapy%5BTitle%5D)+AND+%22Nanoscale%22%5BJournal%5D)">Magnetic particle imaging: advancements and perspectives for real-time in vivo monitoring and image-guided therapy.</a> Nanoscale. 5 (10), 4040-4055 (2013).</li>
<li>Bulte, J. W. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Quantitative+%26%2334%3Bhot-spot%26%2334%3B+imaging+of+transplanted+stem+cells+using+superparamagnetic+tracers+and+magnetic+particle+imaging%5BTitle%5D)+AND+%22Tomography%22%5BJournal%5D)">Quantitative &#34;hot-spot&#34; imaging of transplanted stem cells using superparamagnetic tracers and magnetic particle imaging.</a> Tomography. 1 (2), 91-97 (2015).</li>
<li>Lemaster, J. E., Chen, F., Kim, T., Hariri, A., Jokerst, J. V. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Development+of+a+trimodal+contrast+agent+for+acoustic+and+magnetic+particle+imaging+of+stem+cells%5BTitle%5D)+AND+%22ACS+Appl+Nano+Mater%22%5BJournal%5D)">Development of a trimodal contrast agent for acoustic and magnetic particle imaging of stem cells.</a> ACS Appl Nano Mater. 1 (3), 1321-1331 (2018).</li>
<li>Shalaby, N., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Complementary+early-phase+magnetic+particle+imaging+and+late-phase+positron+emission+tomography+reporter+imaging+of+mesenchymal+stem+cells+in+vivo%5BTitle%5D)+AND+%22Nanoscale%22%5BJournal%5D)">Complementary early-phase magnetic particle imaging and late-phase positron emission tomography reporter imaging of mesenchymal stem cells in vivo.</a> Nanoscale. 15 (7), 3408-3418 (2023).</li>
<li>Wang, Q., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Artificially+engineered+cubic+iron+oxide+nanoparticle+as+a+high-performance+magnetic+particle+imaging+tracer+for+stem+cell+tracking%5BTitle%5D)+AND+%22ACS+Nano%22%5BJournal%5D)">Artificially engineered cubic iron oxide nanoparticle as a high-performance magnetic particle imaging tracer for stem cell tracking.</a> ACS Nano. 14 (2), 2053-2062 (2020).</li>
<li>Li, X., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Extravascular+sources+of+lung+angiotensin+peptide+synthesis+in+idiopathic+pulmonary+fibrosis%5BTitle%5D)+AND+%22Am+J+Physiol+Lung+Cell+Mol+Physiol%22%5BJournal%5D)">Extravascular sources of lung angiotensin peptide synthesis in idiopathic pulmonary fibrosis.</a> Am J Physiol Lung Cell Mol Physiol. 291 (5), L887-L895 (2006).</li>
</ol>

The authors have no conflicts of interest to disclose.

Intratracheal instillation in mice is a precise technique for delivering substances directly into the lungs. Careful attention is required during multiple critical steps throughout this procedure. Starting with ensuring proper depth of anesthesia to prevent discomfort and movement and positioning the mouse supine with the neck extended to align the airway for clear access to the tracheal opening. Use of a tongue depressor may help keep the airway open. Make sure that the catheter is carefully inserted and the substances ...

Cell therapy1,2 offers regenerative potential, promoting tissue repair, reducing inflammation, and improving outcomes in chronic diseases like leukemia and lymphoma3,4 (hematopoietic stem cells), osteoarthritis5,6 (mesenchymal stem cells), type 1 diabetes7 (islet cell transplantation), spinal cord injuries8,9, neurodegenerative diseases10,11,12 (neural stem cells), and lung fibrosis13,14,15,16 (pulmonary progenitor cells). These therapies offer significant potential, though challenges like immune rejection and long-term efficacy still remain17,18. Pulmonary fibrosis (PF) is a chronic and progressive lung disease characterized by excessive scarring of lung tissue, leading to impaired lung function19. Cell therapy for PF aims to regenerate damaged lung tissue and reduce fibrosis by introducing regenerative cells, such as mesenchymal stem cells or distal lung progenitor cells, into the affected lungs20. Distal lung progenitor cells, which include populations like basal cells, alveolar type II cells, bronchioalveolar stem cells, and other multipotent progenitor cells, have the ability to promote tissue repair, reduce inflammation, potentially regenerate damaged lung tissue, and reverse some of the lung damage while restoring normal lung function21. Several preclinical and early-stage clinical studies have shown that transplanting lung progenitor cells into fibrotic lungs can help regenerate alveolar structures, promote tissue remodeling, and reduce inflammation13,22,23. Additionally, these cells can secrete various growth factors and cytokines that modulate the fibrotic environment, further promoting repair. Despite the encouraging results in improving lung function, challenges remain in optimizing cell delivery, including efficient isolation, expansion, and integration of these cells into the damaged lung tissue, ensuring long-term safety, and preventing unwanted side effects. Continued research is needed to refine protocols and assess the long-term safety and efficacy of progenitor cell therapies for pulmonary fibrosis.
Transplanting cells into the lungs for pulmonary fibrosis involves several techniques, each designed to improve cell delivery, survival, and integration into the damaged lung tissue. Common methods include intravenous injection24,25, endobronchial delivery26,27, and intratracheal instillation28,29,30,31, each with specific advantages and challenges. Intravenous administration of stem cells is hindered by suboptimal pulmonary homing, sequestration in off-target organs, limited post-infusion viability, and the risk of immunogenic responses. Endobronchial delivery, though more localized, is constrained by heterogeneous cell distribution, potential airway occlusion, inflammatory responses, and procedural challenges within fibrotic lung architecture. Similarly, intratracheal instillation, despite enabling direct pulmonary deposition, may lead to inconsistent cell dispersion, inadequate distal lung penetration, localized irritation, and variability in dose uniformity across lung compartments. Although all these techniques aim to improve cell survival, integration, and efficacy in regenerating lung tissue, the choice of optimal technique depends on factors like the type of cells being transplanted, the stage of fibrosis, and the patient&#39;s overall health.
Despite its challenges, intratracheal instillation remains one of the most commonly used methods for delivering cells directly to the lungs, especially in the context of pulmonary fibrosis. In this technique, cells are introduced into the lung via a catheter inserted into the trachea32. The cells are then deposited in the alveolar space, where they can potentially repair the damaged lung tissue. This method is minimally invasive and relatively easy to perform compared to other delivery approaches like ex vivo lung perfusion. As the cells are directly deposited into the lungs, it can improve the chances of effective integration and repair. Unlike intravenous injection, intratracheal instillation avoids systemic circulation, reducing the risk of cells being trapped in other organs like the liver or spleen, leading to a more focused therapeutic effect in the lungs. Despite these benefits, the method still faces challenges in terms of suboptimal cell distribution and retention, and survival within the lungs, which can limit therapeutic effectiveness. Ongoing research is working to refine this approach for more effective clinical outcomes. Researchers can determine if intratracheal instillation is suitable for their applications by evaluating several factors. These include the type of cells being delivered, their ability to survive and integrate into lung tissue, and the severity of the disease model (i.e., pulmonary fibrosis).
Imaging is an indispensable tool for tracking cells, assessing their viability, distribution, and effects, enhancing cell therapy monitoring and optimization of treatment strategies33. Researchers have assessed delivery efficiency through imaging and postdelivery analysis to track cell distribution and retention. Various techniques like fluorescence, Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), and ultrasound have been used to track labeled stem cells for pulmonary fibrosis. However, they face limitations like low depth penetration (fluorescence), poor sensitivity (MRI), radiation exposure (CT, PET, SPECT), and low resolution (ultrasound)34. Although optimizing imaging contrast, resolution, and biocompatibility can help overcome these challenges to a certain extent, exploring newer imaging techniques can also prove essential for accurate stem cell tracking in lungs. In recent years, Magnetic Particle Imaging (MPI) has emerged as a promising, radiation-free imaging modality, which offers high sensitivity, real-time, quantitative imaging with high contrast without background interference.
MPI uses superparamagnetic iron oxide nanoparticles (SPIONs) for direct visualization, and its working principle is based on the non-linear magnetization response of these SPIONs when exposed to a time-varying magnetic field35,36. Electromagnets are used to create a field-free region (FFR), where only particles within this region exhibit non-linear magnetization and generate a signal when excited by an oscillating magnetic field. On the other hand, the magnetization of particles outside this FFR is saturated, and they do not participate in signal production. By systematically moving the FFR throughout the imaging volume, MPI constructs spatial maps of the nanoparticle distribution and subsequent images. MPI offers several advantages over traditional imaging modalities37,38. Unlike MRI or CT, MPI provides signal only from the tracer, resulting in zero background noise and exceptional contrast. It offers real-time imaging with high temporal resolution, making it ideal for tracking dynamic processes such as cell migration or perfusion. Additionally, MPI is highly sensitive, allowing for the detection of small quantities of SPIONs without ionizing radiation, unlike PET or CT. Furthermore, it also demonstrates excellent linear quantification, enabling accurate assessment of tracer concentration. Overall, MPI combines the strengths of sensitivity, safety, and quantification, making it a powerful tool for biomedical imaging. MPI is promising for stem cell tracking in lungs, enabling precise monitoring of cell migration, retention, and therapeutic effects. It provides excellent contrast without tissue signal interference, thereby enabling precise localization of labeled stem cells39,40,41,42. The following sections outline the protocols undertaken for these studies, demonstrating the use of intratracheal instillation to deliver the labeled cells to mouse lungs and confirmation via MPI.

<table><tbody><tr><td>1.7 mL microcentrifuge tube</td><td>DOT Scientific</td><td>RN1700-GMT</td><td>For cell collection and prepraring BLM dilutions</td></tr><tr><td>Anti-Dextran antibdoy</td><td>STEMCELL Technologies</td><td>60026</td><td>Primary Antibody</td></tr><tr><td>BD Luer-Lok&amp;nbsp;Syringe</td><td>Becton, Dickinson</td><td>309628</td><td>For air injections during intratracheal instillation</td></tr><tr><td>Cytospin 3</td><td>Thermo Shandon</td><td>74010121GB</td><td></td></tr><tr><td>DNase I</td><td>Millipore-Sigma</td><td>10104159001</td><td></td></tr><tr><td>Dulbecco&#039;s phosphate-buffered saline (DPBS -/-)&amp;nbsp;</td><td>Gibco</td><td>14190250</td><td></td></tr><tr><td>Fetal Bovine Serum&amp;nbsp;</td><td>ThermoFisher Scientific</td><td>A5670701</td><td></td></tr><tr><td>Gentamicin&amp;nbsp;</td><td>Gibco</td><td>15750060</td><td></td></tr><tr><td>Goat anti-Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor&amp;trade; 568</td><td>ThermoFisher Scientific</td><td>A-11004</td><td>Secondary Antibody</td></tr><tr><td>Goat Serum</td><td>Millipore-Sigma</td><td>G9023</td><td></td></tr><tr><td>Isoflurane</td><td>Covetrus</td><td>11695067772</td><td>Gas anesthesia</td></tr><tr><td>Isoflurane vaporizer</td><td>SOMNI Scientific</td><td>VS6002</td><td>Anethesia apparatus</td></tr><tr><td>Momentum</td><td>Magnetic Insight Inc</td><td></td><td>Preclinical Magnetic Particle Imaging (MPI) scanner</td></tr><tr><td>Mouse intubation kit</td><td>OHAN</td><td>Ohan-201</td><td>Complete intubation kit with all the required accessories</td></tr><tr><td>NOD/SCID Mice</td><td>Jackson Laboratory</td><td>RRID:IMSR_JAX:001303</td><td>Immunocompromised mouse model</td></tr><tr><td>Penicillin/Streptomycin&amp;nbsp;</td><td>Gibco</td><td>15140122</td><td></td></tr><tr><td>PneumaCult-Ex Plus Medium&amp;nbsp;</td><td>STEMCELL Technologies</td><td>5040</td><td></td></tr><tr><td>ProLong Diamond Antifade Mountant with DAPI&amp;nbsp;</td><td>Invitrogen</td><td>P36962</td><td>Mounting medium for immunostained slides</td></tr><tr><td>Protease from Streptomyces griseus&amp;nbsp;</td><td>Millipore-Sigma</td><td>P5147</td><td></td></tr><tr><td>Surgical kit</td><td></td><td></td><td>Blunt-end forceps used for holding tongue of the. Mouse</td></tr><tr><td>Tris-Buffered Saline with Tween20 (TBST)</td><td>ThermoFisher Scientific</td><td>28360</td><td></td></tr><tr><td>TrypLE Express Enzyme&amp;nbsp;</td><td>ThermoFisher Scientific</td><td>12604021</td><td></td></tr><tr><td>VivoTrax Plus</td><td>Magnetic Insight</td><td>MIVTP01</td><td>Iron oxide tracer for cell labeling in vitro and subsequent MPI</td></tr></tbody></table>

image-guided in vivo tracking of transplanted distal lung epithelial progenitor cells for pulmonary fibrosis using magnetic particle imaging

Image-guided In Vivo Tracking of Transplanted Distal Lung Epithelial Progenitor Cells for Pulmonary Fibrosis Using Magnetic Particle Imaging

Pulmonary fibrosis (PF) is a progressive and chronic lung disease characterized by repeated alveolar epithelial injury that leads to excessive extracellular matrix deposition, resulting in tissue thickening, scarring, and impaired gas exchange, leading to respiratory dysfunction. In the United States, around 50,000 new cases are reported annually, with patients facing serious complications such as pneumothorax, pulmonary hypertension, respiratory failure, and an increased risk of lung cancer. Current therapeutic options are limited in efficacy and primarily aim to slow disease progression. Cell therapy has emerged as a promising intervention, offering the potential to regenerate damaged lung tissue, modulate inflammation, and improve pulmonary function. However, the effectiveness of these therapies depends significantly on the ability to monitor the distribution, survival, and integration of transplanted cells within the host lungs. 
Magnetic Particle Imaging (MPI) is a novel, non-invasive, preclinical imaging modality that utilizes superparamagnetic iron oxide nanoparticles (SPIONs) as tracers. MPI offers high sensitivity, specificity, and no background signal, allowing for real-time and quantitative tracking of labeled cells in vivo. In this study, we investigated the use of MPI for monitoring human distal lung epithelial progenitor cells transplanted into the lungs of immunocompromised mice. Cells were labeled with varying SPION concentrations to optimize the signal, confirmed by immunostaining and iron quantification. After intratracheal instillation, 2D MPI scans were acquired to track the spatial distribution of transplanted cells. Longitudinal imaging over 2 weeks enabled visualization of cell integration and retention within lung tissue. Successful instillation exhibited MPI signals in both left and right lungs, which decreased (~65%) over time. Mice were subsequently sacrificed for histological validation. This study demonstrates the utility of MPI for noninvasive, longitudinal tracking of cell therapy in pulmonary fibrosis, and pivots around the intricate techniques utilized during the procedures.

The pilot study was undertaken with six mice. Out of these, only one mouse died before the completion of the study, at day 10. 2D MPI signal intensities for different labeling concentrations were assessed as a function of the number of cells (Figure 1A). It was observed that the signal intensity was directly proportional to the concentration of the iron oxide tracer. Therefore, the concentration of 250 µg/mL was considered as the optimal labeling concentration and used for subsequent studies...

Cell therapy offers a promising intervention for pulmonary fibrosis by using progenitor cells to repair damaged tissue and improve lung function. As imaging plays a pivotal role in tracking cell integration, herein, we describe magnetic particle imaging-guided in vivo tracking of cell therapy for pulmonary fibrosis in a mouse model.

Pulmonary fibrosis (PF) is a progressive and chronic lung disease characterized by repeated alveolar epithelial injury that leads to excessive ...

This study focuses on intratracheal intubation protocol as a critical delivery method for lung cell therapy, aiming to optimize cell transplantation and non-invasive tracking using magnetic particle imaging in pulmonary fibrosis. Our protocol addresses the lack of non-invasive methods for in vivo tracking of cell therapy in pulmonary fibrosis by combining intratracheal insulation with magnetic particle imaging to monitor cell distribution. Our protocol offers precise localized cell delivery via intratracheal installation and superior tracking using magnetic particle imaging, providing high sensitivity, real-time imaging with no background noise.To begin, weigh a 12-week-old male NOD or SCID mouse to calculate the required dose of bleomycin. Prepare the bleomycin solution in sterile saline at the desired concentration to a final volume of 50 microliters in a 1.7-milliliter microcentrifuge tube. Then load the solution into a pipette.Preload a syringe with 200 microliters of air to ensure the entire liquid volume is expelled into the trachea while injecting. After anesthetizing the mouse, assemble the fiber light intubation kit with the optical fiber probe threaded through the laryngoscope and catheter. Pinch the animal's toe to confirm adequate anesthesia and apply ophthalmic ointment to both eyes whenever the animal is under anesthesia.Suspend the mouse by its incisors in the supine position on an angled rodent intubation stand. Using blunt-ended forceps, grasp the tongue and gently move it upward and leftward to expose the larynx for clear visualization. Turn on the fiber optic probe and guide it into the mouth to approach the trachea.Use the magnifier of the laryngoscope to enhance visibility and identify the vocal cords at the tracheal opening. Insert the catheter into the tracheal opening and gently remove the laryngoscope. Then place a 20 microliter droplet of saline at the upper end of the catheter.Attach the syringe preloaded with 200 microliters of air and push the droplet into the trachea. Next, load the catheter with up to 50 microliters of bleomycin and instill it using the air-filled syringe. Keep the catheter in place for 5-7 seconds to prevent backflow of the liquid from the trachea.Then gently remove the catheter. Maintain the mouse on the intubation stand in the same position for at least 30 seconds. Then remove the mouse from the stand and place it in a recovery cage positioned on a heating pad.Monitor the mouse continuously until it fully recovers from anesthesia. Obtain nanoparticle labeled human airway epithelial cells from patients with idiopathic pulmonary fibrosis. 72 hours after bleomycin installation, re-anesthetize the mouse and repeat the intratracheal installation procedure to administer 50, 000 cells in 50 microliters of cell suspension.Let the mouse recover for at least 20 minutes before magnetic particle imaging. Set up the mouse bed in the magnetic particle imaging scanner after passing the anesthesia line underneath the bed through the correct connectors. While the mouse is being anesthetized, prepare the magnetic particle imaging scanner.After confirming adequate anesthesia with a toe pinched test, carefully position the mouse on the magnetic particle imaging bed. Push the bed with the mouse into the scanner bore and click on Start Scan in the software interface to initiate imaging. After the scan is completed, remove the mouse from the magnetic particle imaging bed and place it into a recovery cage positioned on a heating pad.Finally, analyze the acquired images using image analysis software. The 2D magnetic particle imaging or MPI signal intensity increased proportionally with the concentration of the iron oxide tracer across all tested cell counts. A concentration of 250 micrograms per milliliter was selected as the optimal labeling concentration.Fluorescence microscopy confirmed successful in vitro labeling of cells, showing red dextran signals in the cytoplasm and blue DAPI stained nuclei. Signal intensities in 2D MPI images increased with the number of labeled cells, confirming a positive correlation between signal and cell count. Based on this, 50, 000 cells were selected for transplantation.The empty bed control image showed no background MPI signal, confirming specificity of the scanner to labeled cells. The four observed signals correspond to fiducial markers used as controls. Successful transplantation of labeled cells into the lungs produced a distinct butterfly-shaped MPI signal with visible distribution in both lungs, validating effective intratracheal delivery.Incomplete cell installation led to signal appearing in both lungs and neck region, indicating leakage due to premature catheter removal. Misplacement of the catheter into the esophagus instead of the trachea caused the MPI signal to appear lower in the abdomen, indicating deposition of cells in the stomach. 14 days after transplantation, ex vivo imaging of the excised lungs confirmed the persistence of labeled cells.Our findings will improve diagnostic accuracy and enable development of targeted therapies for pulmonary diseases, including stem cell therapy, accelerating progress and innovation in lung imaging and related biomedical fields. Our laboratory will focus on augmenting stem cell-based therapies for lung fibrosis, enhancing non-invasive imaging techniques while aiming to optimize cell delivery and monitor therapeutic efficacy for pulmonary fibrosis.

image-guided-vivo-tracking-transplanted-distal-lung-epithelial

Research

JoVE Journal

Medicine

We describe an in vivo fluorescence imaging protocol to monitor muscle regeneration by GFP-labeled myoblasts after transplantation into skeletal muscles of both healthy and dystrophic mice. This protocol can be adapted to study muscle regeneration by transplantation of other types of cells and in other muscular conditions as well.

Tracking Dynamics of Muscle Engraftment in Small Animals by In Vivo Fluorescent Imaging

This article describes an optimized sequence of events for multimodal imaging of cellular grafts in rodent brain using: (i) in vivo bioluminescence and magnetic resonance imaging, and (ii) post mortem histological analysis. Combining these imaging modalities on a single animal allows cellular graft evaluation with high resolution, sensitivity and specificity.

Multimodal Imaging of Stem Cell Implantation in the Central Nervous System of Mice

A non-invasive means to evaluate the success of myoblast transplantation is described. The method takes advantage of a unified fusion reporter gene composed of genes whose expression can be imaged with different imaging modalities. Here, we make use of a fluc reporter gene sequence to target cells via bioluminescence imaging.

Molecular Imaging to Target Transplanted Muscle Progenitor Cells

Tracking of cells using MRI has gained remarkable attention in the past years. This protocol describes the labeling of dendritic cells with fluorine (19F)-rich particles, the in vivo application of these cells, and monitoring the extent of their migration to the draining lymph node with 19F/1H MRI and 19F MRS.

Monitoring Dendritic Cell Migration using 19F / 1H Magnetic Resonance Imaging

Combinatorial 5 fluorescent proteins marking of hematopoietic stem and progenitor cells allows in vivo clonal tracking via confocal and two-photon microscopy, providing insights into bone marrow hematopoietic architecture during regeneration. This method allows non-invasive fate mapping of spectrally-coded HSPCs-derived cells in intact tissues for extensive periods of time following transplantation.<br...

In vivo Clonal Tracking of Hematopoietic Stem and Progenitor Cells Marked by Five Fluorescent Proteins using Confocal and Multiphoton Microscopy

We describe a non-invasive multimodal imaging approach based on Micro-CT and fluorescence molecular tomography for longitudinal assessment of the mouse lung fibrosis model induced by double intratracheal instillation of bleomycin.

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice

This article describes the generation of an orthotopic mouse model of human pleural mesothelioma by implantation of H2052/484 mesothelioma cells into the pleural cavity of immunocompromised athymic mice. The longitudinal monitoring of the development of intrapleural tumors was assessed by non-invasive multimodal [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography imaging.

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Presented here is a protocol for non-invasive mesenchymal stem cell (MSC) delivery and tracking in a mouse model of traumatic brain injury. Superparamagnetic iron oxide nanoparticles are employed as a magnetic resonance imaging (MRI) probe for MSC labeling and non-invasive in vivo tracking following intranasal delivery using real-time MRI.

Tracking Superparamagnetic Iron Oxide-labeled Mesenchymal Stem Cells using MRI after Intranasal Delivery in a Traumatic Brain Injury Murine Model

Here, we present a protocol to intravitally image the transplanted mouse left lung using two-photon microscopy. This represents a valuable tool for studying cellular dynamics and interactions in real-time following murine lung transplantation.

Intravital Two-Photon Microscopy of the Transplanted Mouse Lung

This study presents an orthotopic non-small cell lung cancer (NSCLC) model based on intrapulmonary inoculation of multicellular spheroids of fluorescent A549-iRFP cells. The model recapitulates clinical NSCLC stages and responds to cisplatin, according to dynamic in vivo monitoring of long-wavelength fluorescence.

Construction of An Orthotopic Xenograft Model of Non-Small Cell Lung Cancer Mimicking Disease Progression and Predicting Drug Activities

Learn magnetic particle imaging to track transplanted distal lung epithelial progenitor cells in vivo for pulmonary fibrosis research. This noninvasive method enables real-time monitoring of cell distribution and retention.

Image-guided In Vivo Tracking of Transplanted Distal Lung Epithelial Progenitor Cells for Pulmonary Fibrosis Using Magnetic Particle Imaging (Video) | JoVE Journal

Image-guided In Vivo Tracking of Transplanted Distal Lung Epithelial Progenitor Cells for Pulmonary Fibrosis Using Magnetic Particle Imaging

Explore More Videos